Literature DB >> 25012832

Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer?

Megan E Daly1, Laurel A Beckett2, Allen M Chen3.   

Abstract

PURPOSE: Uncertainty exists regarding the optimal surveillance imaging strategy following stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC), particularly with respect to timing. We sought to determine how routine use of early (<6 months) posttreatment imaging affects subsequent management. METHODS AND MATERIALS: The records of all patients treated with SBRT between January 2007 and January 2013 for early-stage NSCLC were reviewed. Eligible patients underwent ≥ 1 early (defined as within 6 months following SBRT) surveillance imaging study. Radiographic findings and subsequent diagnostic or therapeutic interventions were identified. Proportions and exact 95% confidence intervals (CI) with early posttreatment surveillance findings and altered treatment were calculated, and cases were examined descriptively.
RESULTS: Sixty-two patients with 67 lung tumors underwent 92 early surveillance imaging studies (86 computed tomographic [CT] and 6 positron emission/CT) at a median of 2.1 months (range, 0.1-5.9 months). New lung nodules were identified in 8 patients (13%), leading to a diagnosis of metastatic disease treated with systemic therapy in 2 patients and biopsy proven solitary lung recurrence in 2 patients, both treated successfully with local therapy. Tumor growth meeting Response Evaluation Criteria in Solid Tumors (RECIST) criteria was identified in 1 patient, who was followed with subsequent radiographic regression. In aggregate, the treatment of 4 patients (6.5%, 95% CI 1.7%-15.2%) was altered by early imaging; 2 (3.2%, 95% CI 0.4%-10.8%) with a potentially curative intervention. No predictors for utility of early surveillance were identified.
CONCLUSIONS: Imaging within 6 months following SBRT for early-stage NSCLC resulted in a definitive intervention in approximately 3% of patients. In the era of cost-effective health care, a first scan at 6 months posttreatment may be adequate for most patients. Larger scale prospective studies are needed to address the optimal surveillance regimen following SBRT and to identify patients who may benefit from more aggressive surveillance regimens.
© 2014.

Entities:  

Mesh:

Year:  2013        PMID: 25012832      PMCID: PMC4586160          DOI: 10.1016/j.prro.2013.08.006

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  18 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.

Authors:  Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-27       Impact factor: 7.038

3.  Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors.

Authors:  Nicholas Trakul; Jeremy P Harris; Quynh-Thu Le; Wendy Y Hara; Peter G Maxim; Billy W Loo; Maximilian Diehn
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

4.  Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.

Authors:  Vikram Rao Bollineni; Joachim Widder; Jan Pruim; Johannes A Langendijk; Erwin M Wiegman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-13       Impact factor: 7.038

5.  Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).

Authors:  Jeffrey Rubins; Michael Unger; Gene L Colice
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

6.  Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy.

Authors:  Jianwei Wang; Ning Wu; Matthew D Cham; Ying Song
Journal:  AJR Am J Roentgenol       Date:  2009-10       Impact factor: 3.959

Review 7.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; Baldassarre Stea; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2010-01-13       Impact factor: 6.280

8.  Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.

Authors:  Jeffrey D Bradley; Issam El Naqa; Robert E Drzymala; Marco Trovo; Griffin Jones; Mary Dee Denning
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-30       Impact factor: 7.038

9.  Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.

Authors:  Pia Baumann; Jan Nyman; Morten Hoyer; Berit Wennberg; Giovanna Gagliardi; Ingmar Lax; Ninni Drugge; Lars Ekberg; Signe Friesland; Karl-Axel Johansson; Jo-Asmund Lund; Elisabeth Morhed; Kristina Nilsson; Nina Levin; Merete Paludan; Christer Sederholm; Anders Traberg; Lena Wittgren; Rolf Lewensohn
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.

Authors:  Xu Zhang; Hui Liu; Peter Balter; Pamela K Allen; Ritsuko Komaki; Tinsu Pan; Hubert H Chuang; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-07       Impact factor: 7.038

View more
  5 in total

Review 1.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

2.  Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more.

Authors:  Angel Moran; Megan E Daly
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 3.  Surveillance imaging following definitive radiotherapy for non-small cell lung cancer: What is the clinical impact?

Authors:  Brandon A Dyer; Megan E Daly
Journal:  Semin Oncol       Date:  2018-02-09       Impact factor: 4.929

Review 4.  Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients.

Authors:  L Ceniceros; J Aristu; E Castañón; C Rolfo; J Legaspi; A Olarte; G Valtueña; M Moreno; I Gil-Bazo
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

5.  Helical Therapy is Safe for Lung Stereotactic Body Radiation Therapy Despite Limitations in Achieving Sharp Dose Gradients.

Authors:  Neha P Amin; Adrian Nalichowski; Shauna Campbell; Jal Hyder; Robyn Spink; Andre A Konski; Michael Dominello
Journal:  Technol Cancer Res Treat       Date:  2017-11-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.